Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesSTU:IX1 +1.45%96 Cyclically Adjusted PB Ratio is 56.27 as of Sep. 15, 2026, which is 42% below its 10-year median of 97.84. GuruFocus rates STU:IX1 with a GF Score™ of 96/100 and a GF Value™ of €548.78 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 127 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 98.43% on this metric.
The historical rank and industry rank for IDEXX Laboratories's Cyclically Adjusted PB Ratio or its related term are showing as below:
STU:IX1'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 27.22 Med: 97.84 Max: 246.01
Current: 56.24
During the past years, IDEXX Laboratories's highest Cyclically Adjusted PB Ratio was 246.01. The lowest was 27.22. And the median was 97.84.
STU:IX1's Cyclically Adjusted PB Ratio is ranked worse than 98.43% of 127
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.72
vs STU:IX1: 56.24
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
IDEXX Laboratories's adjusted book value per share data for the three months ended in Jun. 2026 was €17.882. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €7.85 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
IDEXX Laboratories (STU:IX1) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
IDEXX Laboratories Cyclically Adjusted PB Ratio Related Terms
IDEXX Laboratories Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories Cyclically Adjusted PB Ratio Chart
STU:IX1 vs A, IQV, WAT: Cyclically Adjusted PB Ratio Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Cyclically Adjusted PB Ratio falls into.
IDEXX Laboratories Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
IDEXX Laboratories's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 56.27 mean?
IDEXX Laboratories (STU:IX1) has a Cyclically Adjusted PB Ratio of 56.27 as of Sep. 15, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors. This is 42% below median its historical median of 97.84. Over the past decade, IDEXX Laboratories' Cyclically Adjusted PB Ratio has ranged from 27.22 to 246.01. According to the industry distribution chart, IDEXX Laboratories ranks #125 out of 127 companies in the Medical Diagnostics & Research industry, placing it in the top 98.4%.
Is IDEXX Laboratories' Cyclically Adjusted PB Ratio too high?
IDEXX Laboratories' current Cyclically Adjusted PB Ratio of 56.27 is 42% below median its 10-year median of 97.84. Over the past 10 years, this metric has ranged from a low of 27.22 to a high of 246.01. The Medical Diagnostics & Research industry median Cyclically Adjusted PB Ratio is 1.72. IDEXX Laboratories' value of 56.27 is 3171.5% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #125 out of 127 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Cyclically Adjusted PB Ratio compare to A and IQV?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #125 out of 127 companies for Cyclically Adjusted PB Ratio. This places IDEXX Laboratories in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.72. IDEXX Laboratories' value of 56.27 is 3171.5% above this benchmark. Historically, IDEXX Laboratories' own Cyclically Adjusted PB Ratio has ranged from 27.22 to 246.01 over the past decade. While the company's 10-year median is 97.84 vs. the industry median of 1.72, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PB Ratio among Medical Diagnostics & Research companies is 1.72, based on 127 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current Cyclically Adjusted PB Ratio of 56.27 is 3171.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PB Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current Cyclically Adjusted PB Ratio is 56.27, which is 42% below median its own 10-year median of 97.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (STU:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €548.78, compared to a current price of €441.70 — trading 19.5% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 56.27, which is 42% below median its 10-year median of 97.84 and 3171.5% above the Medical Diagnostics & Research industry median of 1.72. IDEXX Laboratories' overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For IDEXX Laboratories (STU:IX1), the current Cyclically Adjusted PB Ratio is 56.27 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (STU:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €441.70 is trading 19.5% below its estimated GF Value™ of €548.78.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for STU:IX1:
Cyclically Adjusted PB Ratio: 56.27 (42% below median its 10-year median of 97.84)
GF Value™: €548.78 vs. price of €441.70 (19.5% below fair value)
Industry Position: 3171.5% above the Medical Diagnostics & Research median (#125 of 127)
No single metric tells the full story. See the STU:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for STU:IX1
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IX1 has been successfully added to your 
